Scovella

RSS

Opinion

EMA has issued an opinion on this medicine

velagliflozin
MedicineVeterinaryOpinion

Italian is available via eTranslation, the European Commission's machine translation service.

Translate to Italian | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

On 5 November 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product 'Scovella 15 mg/ml oral solution', intended for non-food-producing horses. The applicant for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.

Scovella is a 'glucoside sodium-dependent glucose co-transporter 2' (SGLT-2) inhibitor medicinal product containing velagliflozin (ATCvet code QA10BK90) as the active substance. Inhibition of SGLT-2 decreases renal glucose reabsorption, which reduces blood glucose levels and thus allows for the control of hyperglycaemia.

The benefits of Scovella are the reduction of hyperinsulinaemia and reduction of associated risk of laminitis in horses with Equine Metabolic Syndrome not responsive to changes in husbandry and exercise regimen.

The most common side effects are elevated triglycerides, elevated liver enzymes, elevated cholesterol, lipaemia and elevated blood urea nitrogen (BUN).

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Scovella and therefore recommends the granting of the marketing authorisation.


Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Product details

Name of medicine
Scovella
Active substance
velagliflozin
International non-proprietary name (INN) or common name
velagliflozin
Species
Horse (non-food-producing)
Anatomical therapeutic chemical veterinary (ATCvet) code
QA10BK90
EMA product number
EMEA/V/C/006610
Marketing authorisation applicant
Boehringer Ingelheim Vetmedica GmbH
Opinion adopted
05/11/2026
Opinion status
Positive
This page was last updated on

Share this page